Skip to main
DOCS
DOCS logo

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 28%
Hold 39%
Sell 6%
Strong Sell 6%

Bulls say

Doximity Inc. has demonstrated robust growth, particularly in its point-of-care (POC) and formulary offerings, which experienced more than 100% increase during the buying season as of February 2024. The company's stock has shown a positive trend, increasing by 3.2% since September 8, indicating a favorable market reaction to recent developments. Furthermore, the guidance for the second quarter appears not only achievable but also potentially offers upside, bolstered by expanding service offerings that enhance visibility and encourage upfront purchasing.

Bears say

Doximity Inc. faces a negative outlook due to the uncertain economic environment, causing pharmaceutical clients to issue downward guidance revisions for fiscal years 2023 and 2024. Additionally, the company is trading at a premium compared to its software peers, raising concerns about potential volatility if it fails to meet high investor expectations. The market will closely monitor Doximity's performance, and any failure to deliver favorable results or raise guidance could lead to significant disappointment among investors.

Doximity (DOCS) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 28% recommend Buy, 39% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 18 analysts, Doximity (DOCS) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.